Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01), Zacks reports.

Compass Therapeutics Stock Performance

Shares of CMPX traded up $0.06 during trading hours on Thursday, hitting $3.03. The company had a trading volume of 449,987 shares, compared to its average volume of 1,980,408. The stock has a market capitalization of $416.21 million, a price-to-earnings ratio of -8.19 and a beta of 1.17. The firm has a fifty day moving average price of $2.52 and a 200-day moving average price of $1.92. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim assumed coverage on Compass Therapeutics in a research note on Monday. They issued a “buy” rating and a $12.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.